Monofer (Ferric Derisomaltose)

Ferric Derisomaltose, the active ingredient in Monofer, is an intravenous iron supplement presented as an injection solution for intravenous infusion use. It is employed to treat iron deficiency anemia in adults, including patients with chronic kidney disease or those requiring rapid iron repletion. Monofer delivers a stable iron‑carbohydrate complex that releases bioavailable iron for hemoglobin synthesis and other iron‑dependent processes.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide across multiple regions and clinics.

Monofer is used to correct iron deficiency anemia and related conditions by providing intravenous iron. - Iron deficiency anemia: restores hemoglobin levels and replenishes depleted iron stores. - Chronic kidney disease-associated anemia: supplies iron when oral supplementation is ineffective or contraindicated. - Perioperative anemia: rapidly corrects iron deficiency before surgery to reduce transfusion requirements.

Monofer may cause adverse reactions ranging from mild to severe; the frequency of each varies among patients.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Headache: transient cranial discomfort. - Dizziness: light‑headed sensation. - Injection site reactions: pain, erythema, or swelling at the infusion site. - Hypotension: temporary drop in blood pressure during or after infusion. - Flushing: brief warmth and reddening of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Severe hypotension: marked blood pressure decline requiring medical intervention. - Hypophosphatemia: significant drop in serum phosphate levels. - Acute respiratory distress: sudden breathing difficulty. - Cardiac arrest: abrupt loss of heart function. - Severe allergic reaction: including angioedema and bronchospasm.

Before initiating Monofer therapy, clinicians should consider several safety measures to minimize risk. - Iron status assessment: confirm iron deficiency with laboratory tests before administration. - Hemoglobin monitoring: check levels regularly to evaluate response. - Phosphate monitoring: observe serum phosphate during and after treatment. - Hypersensitivity history: avoid use in patients with known allergy to ferric derisomaltose or other IV iron products. - Concomitant infection: defer infusion in active severe infections unless benefits outweigh risks. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Monofer can interact with certain medicines or conditions; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Iron overload disorders: risk of excessive iron accumulation. - Concurrent IV iron products: may cause cumulative iron toxicity. - High-dose vitamin C supplements: increase iron absorption and potential overload.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect during infusion. - Erythropoiesis‑stimulating agents: monitor hemoglobin to avoid excessive rise.